and that delay could allow competitors seeking to eat into a market for chronic dry eye disease currently dominated by Xiidra and AbbVie's Restasis (cyclosporine). Sales of the two drugs were $334 ...

But with Novartis failing to convince European regulators about the merits of Xiidra last year, and Allergan's ageing Restasis potentially facing generic competition, there’s a lot to play for ...